Mainz Biomed (NASDAQ:QUCY) Issues Earnings Results

Mainz Biomed (NASDAQ:QUCY) released its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.97 million for the quarter.

Mainz Biomed Price Performance

Shares of QUCY stock traded down $0.06 on Thursday, hitting $0.56. 349,700 shares of the stock traded hands, compared to its average volume of 6,029,565. The company has a market capitalization of $8.27 million, a PE ratio of -0.05 and a beta of 2.42. Mainz Biomed has a 1-year low of $0.30 and a 1-year high of $4.93. The company’s fifty day moving average is $1.15 and its 200 day moving average is $1.26.

Wall Street Analysts Forecast Growth

A number of research firms have commented on QUCY. Litchfield Hills Research upgraded shares of Mainz Biomed to a “strong-buy” rating in a research note on Monday, August 10th. Weiss Ratings downgraded shares of Mainz Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Finally, Zacks Research raised shares of Mainz Biomed to a “hold” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Mainz Biomed currently has an average rating of “Hold”.

About Mainz Biomed

Mainz Biomed N.V. is a molecular genetics diagnostics company focused on developing noninvasive tests for the early detection of cancer. The company is headquartered in Mainz, Germany, and its ordinary shares trade on the Nasdaq Capital Market under the symbol QUCY. Its primary product is ColoAlert, a stool-based molecular diagnostic test designed to detect genetic and molecular biomarkers associated with colorectal cancer and advanced adenomas. The test is intended to offer a noninvasive alternative to screening methods that require a procedure, and it has been marketed in Germany and other European markets following receipt of European regulatory clearance.